GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Eric Stier sold 1,652 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $6.83, for a total transaction of $11,283.16. Following the completion of the transaction, the senior vice president now owns 240,102 shares of the company’s stock, valued at approximately $1,639,896.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Eric Stier also recently made the following trade(s):
- On Monday, February 25th, Eric Stier sold 11,243 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.80, for a total transaction of $76,452.40.
GenMark Diagnostics stock traded up $0.04 during mid-day trading on Friday, reaching $6.71. The company had a trading volume of 1,170 shares, compared to its average volume of 353,912. GenMark Diagnostics, Inc has a 1 year low of $3.58 and a 1 year high of $8.81. The company has a current ratio of 3.93, a quick ratio of 3.40 and a debt-to-equity ratio of 1.96. The stock has a market cap of $398.63 million, a PE ratio of -7.47 and a beta of 1.55.
GenMark Diagnostics (NASDAQ:GNMK) last issued its earnings results on Tuesday, April 30th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01). GenMark Diagnostics had a negative net margin of 71.40% and a negative return on equity of 137.04%. The company had revenue of $21.53 million during the quarter, compared to analysts’ expectations of $21.08 million. On average, sell-side analysts forecast that GenMark Diagnostics, Inc will post -0.81 EPS for the current fiscal year.
A number of equities research analysts have recently commented on GNMK shares. Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, January 25th. BidaskClub cut shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, February 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of GenMark Diagnostics in a report on Friday, February 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $9.67.
Hedge funds have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. boosted its position in GenMark Diagnostics by 123.3% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,466 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 2,466 shares during the last quarter. OLD National Bancorp IN boosted its position in GenMark Diagnostics by 5.9% during the fourth quarter. OLD National Bancorp IN now owns 48,475 shares of the medical equipment provider’s stock worth $236,000 after acquiring an additional 2,700 shares during the last quarter. Swiss National Bank boosted its position in GenMark Diagnostics by 3.3% during the first quarter. Swiss National Bank now owns 96,800 shares of the medical equipment provider’s stock worth $686,000 after acquiring an additional 3,100 shares during the last quarter. Legal & General Group Plc boosted its position in GenMark Diagnostics by 48.6% during the fourth quarter. Legal & General Group Plc now owns 11,308 shares of the medical equipment provider’s stock worth $55,000 after acquiring an additional 3,700 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in GenMark Diagnostics by 3.1% during the fourth quarter. Two Sigma Investments LP now owns 180,488 shares of the medical equipment provider’s stock worth $877,000 after acquiring an additional 5,507 shares during the last quarter. Institutional investors and hedge funds own 91.76% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thestockobserver.com/2019/05/24/insider-selling-genmark-diagnostics-inc-gnmk-svp-sells-1652-shares-of-stock.html.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Featured Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.